Therapeutic Drugs and Their Management

[1]  J. Fung,et al.  Measurement of CD4+ T‐cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation , 2010, Clinical transplantation.

[2]  J. Pelt,et al.  Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. , 2010 .

[3]  Suri Pappu,et al.  Signature sequence validation of human papillomavirus type 16 (HPV-16) in clinical specimens , 2009, Journal of Clinical Pathology.

[4]  G. McMillin,et al.  Analytical Support of Classical Anticonvulsant Drug Monitoring beyond Immunoassay: Application of Chromatographic Methods , 2009 .

[5]  H. Brauch,et al.  Pharmacogenomics of tamoxifen therapy. , 2009, Clinical chemistry.

[6]  D. Kuypers,et al.  New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation , 2009, Therapeutic drug monitoring.

[7]  J. McCune,et al.  Busulfan in hematopoietic stem cell transplant setting , 2009, Expert opinion on drug metabolism & toxicology.

[8]  S. Sleijfer,et al.  The applicability of mTOR inhibition in solid tumors. , 2009, Current cancer drug targets.

[9]  V. Haufroid,et al.  Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference , 2009, Therapeutic drug monitoring.

[10]  J. Chládek,et al.  An improved high‐performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis , 2009, Biopharmaceutics & drug disposition.

[11]  G. Sani,et al.  Antipsychotic and antiepileptic drugs in bipolar disorder: the importance of therapeutic drug monitoring. , 2009, Current medicinal chemistry.

[12]  S. Zisook,et al.  Is there a therapeutic window with some antidepressants for analgesic response? , 2009, Current pain and headache reports.

[13]  S. Rajapakse.  Management of yellow oleander poisoning , 2009, Clinical toxicology.

[14]  A. Carlsson,et al.  The 'atypicality' of antipsychotics: a concept re-examined and re-defined , 2009, Nature Reviews Drug Discovery.

[15]  D. Adu,et al.  Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis , 2009, Transplantation.

[16]  Robert J Riley,et al.  Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  G. Pasternak,et al.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. , 2009, The journal of pain : official journal of the American Pain Society.

[18]  A. Nafziger,et al.  Utility and Application of Urine Drug Testing in Chronic Pain Management With Opioids , 2009, The Clinical journal of pain.

[19]  L. Hilbrands,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2008, The New England journal of medicine.

[20]  R. Bies,et al.  Suboptimal Aminoglycoside Dosing in Critically Ill Patients , 2008, Therapeutic drug monitoring.

[21]  D. Denning,et al.  Therapeutic drug monitoring for triazoles , 2008, Current opinion in infectious diseases.

[22]  U. S. Justesen.  Protease inhibitor plasma concentrations in HIV antiretroviral therapy. , 2008, Danish medical bulletin.

[23]  D. Andes,et al.  Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications , 2008, Antimicrobial Agents and Chemotherapy.

[24]  P. Striano,et al.  Limited place for plasma monitoring of new antiepileptic drugs in clinical practice. , 2008, Medical science monitor : international medical journal of experimental and clinical research.

[25]  D. Kuypers,et al.  Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. , 2008, Annals of transplantation.

[26]  Debra L. Stevens.  Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome , 2008, The Annals of pharmacotherapy.

[27]  R. Beran,et al.  Value of therapeutic drug level monitoring and unbound (free) levels , 2008, Seizure.

[28]  W. Vigneswaran,et al.  Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[29]  Ivanović Jelena,et al.  Therapeutic drug monitoring in the management of HIV-infected patients. , 2008 .

[30]  A. Camm.  Safety considerations in the pharmacological management of atrial fibrillation. , 2008, International journal of cardiology.

[31]  B. Bourgeois,et al.  Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies , 2008, Epilepsia.

[32]  J. Donnelly,et al.  Therapeutic Drug Monitoring of Voriconazole , 2008, Therapeutic drug monitoring.

[33]  Edoardo Spina,et al.  Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. , 2008, Clinical therapeutics.

[34]  A. Terry,et al.  Bioanalytical methods for the determination of antipsychotic drugs. , 2008, Biomedical chromatography : BMC.

[35]  L. Shaw,et al.  Multicenter Evaluation of a New Inosine Monophosphate Dehydrogenase Inhibition Assay for Quantification of Total Mycophenolic Acid in Plasma , 2008, Therapeutic drug monitoring.

[36]  A. Sánchez-Fructuoso.  Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials , 2008 .

[37]  S. Johannessen,et al.  Value of therapeutic drug monitoring in epilepsy , 2008, Expert review of neurotherapeutics.

[38]  P. Thall,et al.  Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  H. Lipp.  Antifungal agents – clinical pharmacokinetics and drug interactions , 2008, Mycoses.

[40]  H. Lyall,et al.  Presentation, diagnosis and management of tuberculosis in HIV‐infected children in the UK , 2008, HIV medicine.

[41]  D. Burger,et al.  Use of therapeutic drug monitoring in HIV disease , 2008, Current opinion in HIV and AIDS.

[42]  K. Wesnes,et al.  Cognitive Performance and Morning Levels of Salivary Cortisol and α-Amylase in Children Reporting High vs. Low Daily Stress Perception , 2008, The Spanish Journal of Psychology.

[43]  A. Dasgupta.  Herbal Supplements and Therapeutic Drug Monitoring: Focus on Digoxin Immunoassays and Interactions With St. John's Wort , 2008, Therapeutic drug monitoring.

[44]  G. Ecker,et al.  Computational models for prediction of interactions with ABC-transporters. , 2008, Drug discovery today.

[45]  M. Woodward,et al.  How are Azathioprine and 6‐mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice , 2008, Inflammatory bowel diseases.

[46]  L. Manchikanti,et al.  Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. , 2008, Pain physician.

[47]  J. Towbin,et al.  Assessment of the Cylex ImmuKnow cell function assay in pediatric heart transplant patients. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[48]  B. Andersson,et al.  High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[49]  Robert A Newman,et al.  Cardiac glycosides as novel cancer therapeutic agents. , 2008, Molecular interventions.

[50]  Z. Dvořák,et al.  Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. , 2008, Current drug metabolism.

[51]  H. Neels,et al.  Relevant Issues in the Monitoring and the Toxicology of Antidepressants , 2008 .

[52]  M. Goetz,et al.  Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response , 2008, Clinical pharmacology and therapeutics.

[53]  R. Drew,et al.  Antifungal serum concentration monitoring: an update. , 2007, The Journal of antimicrobial chemotherapy.

[54]  M. Barclay,et al.  Red Blood Cell Methotrexate Polyglutamate Concentrations in Inflammatory Bowel Disease , 2007, Therapeutic drug monitoring.

[55]  S. Yun,et al.  Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[56]  Luigi Brunetti,et al.  The impact of abbreviations on patient safety. , 2007, Joint Commission journal on quality and patient safety.

[57]  L. Shaw,et al.  Therapeutic drug monitoring of mycophenolic acid. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[58]  M. Trivedi,et al.  Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. , 2007, CNS spectrums.

[59]  J. Williamson,et al.  Principles of antimicrobial use in older adults. , 2007, Clinics in geriatric medicine.

[60]  P. Juang.  Update on new antifungal therapy. , 2007, AACN advanced critical care.

[61]  P. Gillman.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated , 2007, British journal of pharmacology.

[62]  S. Knight,et al.  The Clinical Benefits of Cyclosporine C2-Level Monitoring: A Systematic Review , 2007, Transplantation.

[63]  J. Turnidge,et al.  Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[64]  H. Lehmkuhl,et al.  Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[65]  J. Coleman,et al.  Pitfalls of testing and summary of guidance on safety monitoring with amiodarone and digoxin , 2007, BMJ : British Medical Journal.

[66]  A. Dasgupta.  Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[67]  J. Garbade,et al.  Pharmacodynamics of T‐cell function for monitoring immunosuppression , 2007, Cell proliferation.

[68]  René H. Levy,et al.  Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII) , 2007, Epilepsy Research.

[69]  J. Gobburu,et al.  Population Pharmacokinetic–Based Dosing of Intravenous Busulfan in Pediatric Patients , 2007, Journal of clinical pharmacology.

[70]  J. Gelow,et al.  Update in the approach to and management of heart failure. , 2006, Southern medical journal.

[71]  P. Carver,et al.  Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants , 2006, Pharmacotherapy.

[72]  J. Kovarik,et al.  Everolimus drug interactions: application of a classification system for clinical decision making , 2006, Biopharmaceutics & drug disposition.

[73]  V. Armstrong,et al.  The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. , 2006, Therapeutic drug monitoring.

[74]  D. Touw,et al.  Pitfalls in TDM of Antibiotic Drugs: Analytical and Modelling Issues , 2006, Therapeutic drug monitoring.

[75]  S. Johannessen,et al.  Valproate: past, present, and future. , 2006, CNS drug reviews.

[76]  P. Gillman,et al.  A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action , 2006, Biological Psychiatry.

[77]  S. Khoo,et al.  An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs , 2006, Therapeutic drug monitoring.

[78]  L. Shaw,et al.  Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation , 2006, Therapeutic drug monitoring.

[79]  K Rowland-Yeo,et al.  A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. , 2006, Current drug metabolism.

[80]  M. Albrecht,et al.  Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. , 2006, Current pharmaceutical design.

[81]  S. Feng,et al.  The Art and Science of Immunosuppression: The Fifth Annual American Society of Transplant Surgeon's State‐of‐the‐Art Winter Symposium , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[82]  S. Hariharan,et al.  A Comparative Study of Sirolimus Tablet Versus Oral Solution for Prophylaxis of Acute Renal Allograft Rejection , 2006, Journal of clinical pharmacology.

[83]  C. Heeschen,et al.  Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. , 2005, Kidney international.

[84]  Sihe Wang,et al.  Immunosuppressants: Pharmacokinetics, methods of monitoring and role of high performance liquid chromatography/mass spectrometry , 2005 .

[85]  E. Seidman,et al.  Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. , 2005, Clinical chemistry.

[86]  G. McMillin,et al.  Effect of Ultrafiltrate Volume on Determination of Free Phenytoin Concentration , 2005, Therapeutic drug monitoring.

[87]  V. Soriano,et al.  Clinical benefit of interventions driven by therapeutic drug monitoring , 2005, HIV medicine.

[88]  David Back,et al.  Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs , 2005, Antiviral therapy.

[89]  M. Kurowski,et al.  Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy , 2005, Antiviral therapy.

[90]  T. Gunji,et al.  Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring * , 2005, Journal of clinical pharmacy and therapeutics.

[91]  J. Zimmerman.  Exposure-response relationships and drug interactions of sirolimus , 2004, The AAPS Journal.

[92]  R. Ridzon,et al.  Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. , 2004, Chest.

[93]  J. Torras,et al.  Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. , 2004, Transplantation.

[94]  B Müller-Oerlinghausen,et al.  The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry , 2004, Pharmacopsychiatry.

[95]  P. Thall,et al.  Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. , 2004, Blood.

[96]  Pal Pacher,et al.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? , 2004, Current pharmaceutical design.

[97]  B. Casetta,et al.  Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction-high performance liquid chromatography-tandem mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[98]  G. Perugi,et al.  Antiepileptic drugs: indications other than epilepsy. , 2004, Epileptic disorders : international epilepsy journal with videotape.

[99]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[100]  F. Bengtsson.  Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". , 2004, Therapeutic drug monitoring.

[101]  P. Taylor.  Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry. , 2004, Therapeutic drug monitoring.

[102]  K. Brayman,et al.  Short sirolimus half‐life in pediatric renal transplant recipients on a calcineurin inhibitor‐free protocol , 2004, Pediatric transplantation.

[103]  Matthias J. Müller,et al.  Therapeutic Monitoring of New Antipsychotic Drugs , 2004, Therapeutic drug monitoring.

[104]  C. Sabbioni,et al.  Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. , 2004, Current medicinal chemistry.

[105]  Jeremy N Ruskin,et al.  National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. , 2004, Archives of internal medicine.

[106]  M. Barclay,et al.  Digoxin therapeutic drug monitoring: an audit and review. , 2003, The New Zealand medical journal.

[107]  N. Fukuoka,et al.  Influence of coadministered antiepileptic drugs on serum phenobarbital concentrations in epileptic patients: quantitative analysis based on a suitable transforming factor. , 2003, Biological & pharmaceutical bulletin.

[108]  S. Soldin,et al.  Phenytoin overview--metabolite interference in some immunoassays could be clinically important: results of a College of American Pathologists study. , 2003, Archives of pathology & laboratory medicine.

[109]  L. Siddoway.  Amiodarone: guidelines for use and monitoring. , 2003, American family physician.

[110]  N. Yasui-Furukori,et al.  Poor Reliability of Therapeutic Drug Monitoring Data for Haloperidol and Bromperidol Using Enzyme Immunoassay , 2003, Therapeutic drug monitoring.

[111]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[112]  T. Tomson,et al.  Therapeutic Drug Monitoring of the Newer Antiepileptic Drugs , 2003, Therapeutic drug monitoring.

[113]  P. Keown,et al.  A Pharmacokinetic and Clinical Review of the Potential Clinical Impact of Using Different Formulations of Cyclosporin A , 2003 .

[114]  D. Holt,et al.  Therapeutic monitoring of sirolimus: its contribution to optimal prescription. , 2003, Transplantation proceedings.

[115]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[116]  R. Mattson,et al.  Interlaboratory Variability in the Quantification of New Generation Antiepileptic Drugs Based on External Quality Assessment Data , 2003, Epilepsia.

[117]  B. Nashan.  Review of the proliferation inhibitor everolimus , 2002, Expert opinion on investigational drugs.

[118]  N. Perico,et al.  Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. , 2002, Kidney international.

[119]  M. Oellerich,et al.  Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. , 2002, Clinical chemistry.

[120]  K. Midtvedt,et al.  Recommendations for the Implementation of Neoral C2 Monitoring in Clinical Practice , 2002, Transplantation.

[121]  L. Shaw,et al.  International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on Immunosuppressive Drug Monitoring , 2002, Therapeutic drug monitoring.

[122]  G. Filler,et al.  Effect of Cyclosporine on Mycophenolic Acid Area Under the Concentration–Time Curve in Pediatric Kidney Transplant Recipients , 2001, Therapeutic drug monitoring.

[123]  M. Barclay,et al.  The therapeutic monitoring of antimicrobial agents. , 2001, British journal of clinical pharmacology.

[124]  V. Armstrong,et al.  Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil. , 2001, Clinical chemistry.

[125]  A. McLachlan,et al.  Validation of methods to study the distribution and protein binding of tacrolimus in human blood. , 2001, Journal of pharmacological and toxicological methods.

[126]  M. Bialer,et al.  Pharmacokinetics of Levetiracetam and Its Enantiomer (R)‐α‐ethyl‐2‐oxo‐pyrrolidine acetamide in Dogs , 2001, Epilepsia.

[127]  W. Sandborn,et al.  Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[128]  L. Shaw,et al.  Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients , 2001, Journal of clinical pharmacology.

[129]  K. Breithaupt-Grögler,et al.  Treatment of congestive heart failure – current status of use of digitoxin , 2001, European journal of clinical investigation.

[130]  R. Kato,et al.  Impairment of mycophenolate mofetil absorption by iron ion , 2000, Clinical pharmacology and therapeutics.

[131]  K. Budde,et al.  Pharmacodynamic Monitoring of Mycophenolate Mofetil , 2000, Clinical chemistry and laboratory medicine.

[132]  J. Coles,et al.  Pediatric utilization of rapamycin for severe cardiac allograft rejection. , 2000, Transplantation.

[133]  J. Gibbs,et al.  Plasma Concentration Monitoring of Busulfan , 2000 .

[134]  G. Levy,et al.  Impact of Absorption Profiling on Efficacy and Safety of Cyclosporin Therapy in Transplant Recipients , 2000, Clinical pharmacokinetics.

[135]  M. Benedetti.  Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies , 2000, Fundamental & clinical pharmacology.

[136]  M. Reis,et al.  Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients , 2000, Acta psychiatrica Scandinavica.

[137]  J. Podbielski,et al.  Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity , 2000, Clinical transplantation.

[138]  K. Brøsen,et al.  Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? , 2000, Therapeutic drug monitoring.

[139]  H. Jung-Cook,et al.  Plasma level monitoring of oxcarbazepine in epileptic patients. , 2000, Archives of medical research.

[140]  T. Moyer,et al.  Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. , 1999, Clinical chemistry.

[141]  R. Fisher,et al.  Expression and inducibility of the human bilirubin UDP‐glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: Evidence for both genetic and environmental influences , 1999, Hepatology.

[142]  L. Shaw,et al.  The apparent inhibition of inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is attributable to the presence of trace quantities of mycophenolic acid. , 1999, Clinical chemistry.

[143]  D. Holt,et al.  Therapeutic drug monitoring of immunosuppressant drugs. , 1999, British journal of clinical pharmacology.

[144]  V. Armstrong,et al.  Identification of glucoside and carboxyl‐linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil , 1999, British journal of pharmacology.

[145]  K. Williams,et al.  Therapeutic drug monitoring: antiarrhythmic drugs. , 1998, British journal of clinical pharmacology.

[146]  A. Nicholls,et al.  Clinical Pharmacokinetics of Mycophenolate Mofetil , 1998, Clinical pharmacokinetics.

[147]  M. Gheorghiade,et al.  Standards of laboratory practice: cardiac drug monitoring , 1998 .

[148]  P. Keck,et al.  Standards of laboratory practice: antidepressant drug monitoring , 1998 .

[149]  M. Privitera,et al.  Standards of laboratory practice: antiepileptic drug monitoring , 1998 .

[150]  T. Johns,et al.  Laboratory guidelines for monitoring of antimicrobial drugs , 1998 .

[151]  B. Uthman,et al.  Intramuscular fosphenytoin (Cerebyx®) in patients requiring a loading dose of phenytoin , 1997, Epilepsy Research.

[152]  Roland Martin,et al.  In vitro modulation of human, autoreactive MBP-specific CD4+ T-cell clones by cyclosporin A , 1997, Journal of Neuroimmunology.

[153]  B. Kahan,et al.  Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration , 1997, Journal of clinical pharmacology.

[154]  G. Granneman,et al.  A single‐dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures , 1997, Neurology.

[155]  E. Perucca.  Pharmacokinetic Profile of Topiramate in Comparison with Other New Antiepileptic Drugs , 1996, Epilepsia.

[156]  K. Hoppu,et al.  Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. , 1996, Transplantation.

[157]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.

[158]  L. Shaw,et al.  Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. , 1995, Clinical chemistry.

[159]  F. Appelbaum,et al.  Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. , 1995, Bone marrow transplantation.

[160]  G. Henze,et al.  High-performance liquid chromatographic determination of methotrexate, 7-hydroxymethotrexate, 5-methyltetrahydrofolic acid and folinic acid in serum and cerebrospinal fluid. , 1994, Journal of chromatography. B, Biomedical applications.

[161]  O. Devinsky,et al.  New Antiepileptic Drugs for Children: Felbamate, Gabapentin, Lamotrigine, and Vigabatrin , 1994, Journal of child neurology.

[162]  M. Relling,et al.  Patient characteristics associated with high-risk methotrexate concentrations and toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  R. W. Schultz,et al.  Pharmacokinetics of gabapentin in subjects with various degrees of renal function , 1994, Clinical pharmacology and therapeutics.

[164]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[165]  R. Ramsay.  Clinical efficacy and safety of gabapentin , 1994, Neurology.

[166]  K. Oka,et al.  Simple and accurate high-performance liquid chromatographic method for the measurement of three antiepileptics in therapeutic drug monitoring. , 1993, Journal of chromatography.

[167]  S. Ferrari,et al.  Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. , 1993, Journal of chemotherapy.

[168]  J. Duffus,et al.  Glossary for chemists of terms used in toxicology (IUPAC Recommendations 1993) , 1993 .

[169]  H. Shirai,et al.  The Long‐Term Effectiveness of Clonazepam Therapy in the Control of Partial Seizures in Children Difficult to Control with Carbamazepine Monotherapy , 1991, The Japanese journal of psychiatry and neurology.

[170]  L. Bowers,et al.  The clinical significance of cyclosporine metabolites. , 1991, Clinical biochemistry.

[171]  A. Richens,et al.  Evaluation of Assay Techniques for the Measurement of Antiepileptic Drugs in Serum: A Study Based on External Quality Assurance Measurements , 1989, Therapeutic drug monitoring.

[172]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[173]  R. Chaganti,et al.  Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide , 1981 .

[174]  I. Leppik,et al.  Primidone kinetics: Effects of concurrent drugs and duration of therapy , 1981, Clinical pharmacology and therapeutics.

[175]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[176]  D. Daly,et al.  Interlaboratory variability in determination of plasma antiepileptic drug concentrations. , 1976, Archives of neurology.

[177]  S. Sato,et al.  Serum clonazepam concentrations in children with absence seizures , 1975, Neurology.

[178]  F. Buchthal,et al.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin. , 1960, Archives of neurology.

[179]  C. Peloquin.  Therapeutic Drug Monitoring in the Treatment of Tuberculosis , 2012, Drugs.

[180]  B. Einollahi,et al.  Approach to a target value for 2-hours post dose cyclosporine (C2) during the first week post renal transplantation. , 2009, Annals of transplantation.

[181]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[182]  C. Uiterwaal,et al.  Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[183]  G. Scheiner-Bobis,et al.  Endogenous and Exogenous Cardiac Glycosides and their Mechanisms of Action , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[184]  M. Pfisterer,et al.  Drug Treatment of Chronic Heart Failure in the Elderly , 2007, Drugs & aging.

[185]  A. Colasanti,et al.  Clinical Pharmacokinetics of Atypical Antipsychotics , 2007, Clinical pharmacokinetics.

[186]  Y. Ueta,et al.  Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. , 2007, Journal of pharmacological sciences.

[187]  T. Tomson,et al.  Pharmacokinetic Variability of Newer Antiepileptic Drugs , 2006, Clinical pharmacokinetics.

[188]  J. Roberts,et al.  Antibacterial Dosing in Intensive Care , 2006, Clinical pharmacokinetics.

[189]  W. Waring.  Management of Lithium Toxicity , 2006, Toxicological reviews.

[190]  M. H. Ensom,et al.  Sirolimus: the evidence for clinical pharmacokinetic monitoring. , 2005, Clinical pharmacokinetics.

[191]  L. Grochow,et al.  Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation , 2004, Cancer Chemotherapy and Pharmacology.

[192]  P. Mitchell.  Therapeutic drug monitoring of non-tricyclic antidepressant drugs , 2004, Clinical chemistry and laboratory medicine.

[193]  A. Macgowan,et al.  The use and therapeutic drug monitoring of teicoplanin in the UK. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[194]  G. Gervasini,et al.  Potential Role of Cerebral Cytochrome P450 in Clinical Pharmacokinetics , 2004, Clinical pharmacokinetics.

[195]  S. Eksborg,et al.  Pharmacokinetic and metabolic studies of high-dose busulphan in adults , 2004, European Journal of Clinical Pharmacology.

[196]  M. Manns,et al.  Clinical Pharmacokinetics of Everolimus , 2004, Clinical pharmacokinetics.

[197]  J. Beijnen,et al.  Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs , 2004, Clinical pharmacokinetics.

[198]  G. Jang,et al.  Dietary Effects on Drug Metabolism and Transport , 2003, Clinical pharmacokinetics.

[199]  S. Soldin,et al.  Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study. , 2003, Archives of pathology & laboratory medicine.

[200]  Richard M Weinshilboum,et al.  Pharmacogenomics and reducing the frequency of adverse drug events. , 2003, Pharmacogenomics.

[201]  T. Ketter,et al.  Pharmacokinetics of mood stabilizers and new anticonvulsants. , 2002, Psychopharmacology bulletin.

[202]  U. Christians,et al.  Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus , 2002, Clinical pharmacokinetics.

[203]  M. Mannel.  Drug Interactions with St John’s Wort , 2001, Canadian family physician Medecin de famille canadien.

[204]  P. Mitchell.  Therapeutic drug monitoring of psychotropic medications. , 2001, British journal of clinical pharmacology.

[205]  J. Zimmerman,et al.  Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. , 2000, Clinical therapeutics.

[206]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[207]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[208]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[209]  S. Eksborg,et al.  Evaluation of clinical assays for measuring high-dose methotrexate in plasma. , 1996, Clinical chemistry.